TTR and amyloidosis: The first siRNA drug, ONPATTRO® (Alnylam Pharmaceuticals Inc.), which was approved by FDA in 2018 for treating hereditary transthyretin-mediated amyloidosis, contains the ionizable lipid MC3 in its LNP formulation [34,35,36,91].